Update on immune-based therapy strategies targeting cancer stem cells

Area of Science:

• Oncology
• Immunology
• Cancer Stem Cell Biology

Background:

• Cancer stem cells (CSCs) are a distinct cell population within tumors.
• CSCs possess self-renewal, heterogeneity, and drug resistance, contributing to metastasis and recurrence.
• Signaling pathways (Notch, EMT, Hh, Wnt) and surface markers (CD44, CD133, EpCAM) are crucial for CSC properties.

Purpose of the Study:

• To review current immunotherapy strategies for targeting cancer stem cells (CSCs).
• To highlight the role of CSCs in tumor recurrence and metastasis.
• To discuss the potential of immunotherapy in overcoming limitations of conventional cancer treatments.

Main Methods:

• Review of pre-clinical and clinical studies on immunotherapy targeting CSCs.
• Focus on various immunotherapy modalities including dendritic cell (DC) vaccines, CAR-T cells, NK-cell therapy, monoclonal antibodies (mAbs), checkpoint inhibitors, and oncolytic viruses (OVs).
• Analysis of CSC-related signaling pathways and surface markers.

Main Results:

• Immunotherapy strategies show promise in targeting CSCs, addressing limitations of chemotherapy and radiation.
• Targeting CSC-specific pathways and markers can potentially eradicate tumors and prevent relapse.
• The review covers both blood malignancies and solid cancers.

Conclusions:

• Immunotherapy represents a novel and effective therapeutic approach for targeting cancer stem cells.
• Combining immunotherapy with existing treatments may improve overall cancer survival.
• Further research and clinical studies are essential to optimize these strategies.